Myeloma Paper of the Day, September 16th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Factors impeding organ recovery despite a deep hematological response in patients with systemic AL amyloidosis varied depending on the organ, and included detectable residual clonal disease.”

Source: Robert Orlowski/X

Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis

Authors: Andrew Staron, Lisa M. Mendelson, Tracy Joshi, Natasha Burke, Vaishali Sanchorawala.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas , including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.